Drug developer Aastrom (ASTM +5.2%) is trading higher after saying the 12-month follow-up data...

|By:, SA News Editor

Drug developer Aastrom (ASTM +5.2%) is trading higher after saying the 12-month follow-up data from clinical trials for its drug ixmyelocel-T showed that treatment was well-tolerated, and efficacy observations were consistent with improved heart function.